OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)

“We are pleased with the continued progress across our PI3Kalpha-focused pipeline, including the steady execution of the PIKture-01 trial of OKI-219. We look forward to sharing updated data from this trial later this month,” said Nicholas Saccomano, president and CEO of OnKure. “We are also excited to announce our next-generation pan-mutant inhibitor development candidate for HR+ metastatic breast cancer this month and provide additional information on our program in vascular malformations later this year. Overall, we believe our progress to date underscores the power of our mutation-selective approach to PI3Kalpha inhibition and reinforces the momentum we are building as we work to deliver scientifically differentiated therapies to patients.”